--- title: "Weight Management Peptides | PepTracker Pro" description: "Peptides studied for body weight regulation and obesity treatment." lang: en json-ld: --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Weight Management # Weight Management Peptides Peptides studied for body weight regulation and obesity treatment. ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/aleniglipron) [\+ Compare](/compare?select=aleniglipron)[](https://app.peptrackerpro.com/?add=aleniglipron) ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/alv-100) [\+ Compare](/compare?select=alv-100)[](https://app.peptrackerpro.com/?add=alv-100) ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/alv-200) [\+ Compare](/compare?select=alv-200)[](https://app.peptrackerpro.com/?add=alv-200) ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/amycretin) [\+ Compare](/compare?select=amycretin)[](https://app.peptrackerpro.com/?add=amycretin) ### ASC30 Low Evidence An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc30) [\+ Compare](/compare?select=asc30)[](https://app.peptrackerpro.com/?add=asc30) ### ASC35 Low Evidence A next-generation once-monthly GLP-1R/GIPR dual agonist peptide with a 14-day half-life (6-fold longer than tirzepatide) and 71% greater weight loss than tirzepatide in preclinical models. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc35) [\+ Compare](/compare?select=asc35)[](https://app.peptrackerpro.com/?add=asc35) ### ASC36 Low Evidence A next-generation once-monthly amylin receptor agonist peptide with a 32-day half-life and 91% greater weight loss than petrelintide in preclinical models. IND filing expected Q2 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc36) [\+ Compare](/compare?select=asc36)[](https://app.peptrackerpro.com/?add=asc36) ### ASC37 Low Evidence A next-generation once-monthly GLP-1R/GIPR/GCGR triple peptide agonist with 5-fold greater potency than retatrutide and a 17-day half-life enabling monthly dosing. IND filing expected Q2 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/asc37) [\+ Compare](/compare?select=asc37)[](https://app.peptrackerpro.com/?add=asc37) ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/asc39) [\+ Compare](/compare?select=asc39)[](https://app.peptrackerpro.com/?add=asc39) ### ASC47 Low Evidence A first-in-class adipose-targeted thyroid hormone receptor beta (THRβ) agonist designed for muscle-preserving weight loss. Phase 1 data at ECO 2026 showed 111.8% greater weight loss when combined with semaglutide vs semaglutide alone. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/asc47) [\+ Compare](/compare?select=asc47)[](https://app.peptrackerpro.com/?add=asc47) ### AT7687 Low Evidence A first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[insulin-sensitivity](/benefits/insulin-sensitivity) [View Details](/peptides/at7687) [\+ Compare](/compare?select=at7687)[](https://app.peptrackerpro.com/?add=at7687) ### Berobenatide Medium Evidence A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/berobenatide) [\+ Compare](/compare?select=berobenatide)[](https://app.peptrackerpro.com/?add=berobenatide) ### BI 3034701 Low Evidence A potential first-in-class triple GLP-1, GIP, and NPY2 receptor agonist peptide entering Phase 2 development mid-2026 for obesity, developed by Boehringer Ingelheim using Gubra-discovered technology. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/bi-3034701) [\+ Compare](/compare?select=bi-3034701)[](https://app.peptrackerpro.com/?add=bi-3034701) ### Bimagrumab Medium Evidence An anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity. [Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Weight Management](/benefits/weight-management)[body-composition](/benefits/body-composition)+1 more [View Details](/peptides/bimagrumab) [\+ Compare](/compare?select=bimagrumab)[](https://app.peptrackerpro.com/?add=bimagrumab) ### BRP Low Evidence A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models. [Appetite Regulation](/benefits/appetite-regulation)[Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/brp) [\+ Compare](/compare?select=brp)[](https://app.peptrackerpro.com/?add=brp) ### BWB3054 Low Evidence A GIP/glucagon dual agonist that achieves weight loss comparable to retatrutide without GLP-1 receptor activity, potentially eliminating GI side effects. Published in Molecular Metabolism (April 2026). [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/bwb3054) [\+ Compare](/compare?select=bwb3054)[](https://app.peptrackerpro.com/?add=bwb3054) ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrilintide) [\+ Compare](/compare?select=cagrilintide)[](https://app.peptrackerpro.com/?add=cagrilintide) ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrisema) [\+ Compare](/compare?select=cagrisema)[](https://app.peptrackerpro.com/?add=cagrisema) ### CAP-GDF15 Low Evidence A newly discovered 12-amino acid anorexigenic peptide derived from the GDF15 prepropeptide region, representing a novel appetite-suppression pathway. [Appetite Regulation](/benefits/appetite-regulation)[Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism) [View Details](/peptides/cap-gdf15) [\+ Compare](/compare?select=cap-gdf15)[](https://app.peptrackerpro.com/?add=cap-gdf15) ### Cotadutide Medium Evidence A once-daily GLP-1/glucagon dual receptor agonist studied for MASH, obesity, and type 2 diabetes with demonstrated liver fat reduction and antifibrotic activity. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/cotadutide) [\+ Compare](/compare?select=cotadutide)[](https://app.peptrackerpro.com/?add=cotadutide) ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. [Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control) [View Details](/peptides/ct-388) [\+ Compare](/compare?select=ct-388)[](https://app.peptrackerpro.com/?add=ct-388) ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/cx11) [\+ Compare](/compare?select=cx11)[](https://app.peptrackerpro.com/?add=cx11) ### DA-1726 Low Evidence A novel once-weekly GLP-1/glucagon dual receptor agonist showing rapid weight loss in Phase 1 trials with preserved lean body mass and direct liver benefits. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/da-1726) [\+ Compare](/compare?select=da-1726)[](https://app.peptrackerpro.com/?add=da-1726) ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/danuglipron) [\+ Compare](/compare?select=danuglipron)[](https://app.peptrackerpro.com/?add=danuglipron) ### Dapiglutide Medium Evidence A long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Gut Health](/benefits/gut-health)[Inflammation](/benefits/inflammation) [View Details](/peptides/dapiglutide) [\+ Compare](/compare?select=dapiglutide)[](https://app.peptrackerpro.com/?add=dapiglutide) ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/ecnoglutide) [\+ Compare](/compare?select=ecnoglutide)[](https://app.peptrackerpro.com/?add=ecnoglutide) ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. [metabolic-health](/benefits/metabolic-health)[Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/efinopegdutide) [\+ Compare](/compare?select=efinopegdutide)[](https://app.peptrackerpro.com/?add=efinopegdutide) ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/efocipegtrutide) [\+ Compare](/compare?select=efocipegtrutide)[](https://app.peptrackerpro.com/?add=efocipegtrutide) ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/eloralintide) [\+ Compare](/compare?select=eloralintide)[](https://app.peptrackerpro.com/?add=eloralintide) ### Enicepatide Medium Evidence An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[appetite-control](/benefits/appetite-control)+1 more [View Details](/peptides/enicepatide) [\+ Compare](/compare?select=enicepatide)[](https://app.peptrackerpro.com/?add=enicepatide) ### GDF-15 Receptor Agonists Medium Evidence A new class of peptide-based weight loss therapeutics that act through the GFRAL/RET receptor in the brainstem, representing a non-GLP-1 mechanism for appetite suppression and energy expenditure regulation. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/gdf15-agonists) [\+ Compare](/compare?select=gdf15-agonists)[](https://app.peptrackerpro.com/?add=gdf15-agonists) ### GEP-44 Low Evidence A novel triple agonist peptide targeting GLP-1 and peptide YY receptors Y1 and Y2, designed to suppress appetite and improve glycemic control while avoiding GI side effects common to first-generation GLP-1 drugs. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/gep-44) [\+ Compare](/compare?select=gep-44)[](https://app.peptrackerpro.com/?add=gep-44) ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/glp1-gip-lani) [\+ Compare](/compare?select=glp1-gip-lani)[](https://app.peptrackerpro.com/?add=glp1-gip-lani) ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[blood-sugar-control](/benefits/blood-sugar-control)+1 more [View Details](/peptides/kai-7535) [\+ Compare](/compare?select=kai-7535)[](https://app.peptrackerpro.com/?add=kai-7535) ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/maridebart-cafraglutide) [\+ Compare](/compare?select=maridebart-cafraglutide)[](https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/maritide) [\+ Compare](/compare?select=maritide)[](https://app.peptrackerpro.com/?add=maritide) ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/mazdutide) [\+ Compare](/compare?select=mazdutide)[](https://app.peptrackerpro.com/?add=mazdutide) ### MBX 4291 Low Evidence A GLP-1/GIP co-agonist prodrug engineered for once-monthly dosing using MBX Biosciences' PEP platform. Phase 1 blinded data showed 7% mean weight loss at 8 weeks with minimal GI side effects. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/mbx-4291) [\+ Compare](/compare?select=mbx-4291)[](https://app.peptrackerpro.com/?add=mbx-4291) ### MBX 5765 Low Evidence A novel quadruple agonist prodrug combining GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single molecule, designed for once-monthly dosing and superior efficacy. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/mbx-5765) [\+ Compare](/compare?select=mbx-5765)[](https://app.peptrackerpro.com/?add=mbx-5765) ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[appetite-control](/benefits/appetite-control) [View Details](/peptides/met-097i) [\+ Compare](/compare?select=met-097i)[](https://app.peptrackerpro.com/?add=met-097i) ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/met-233i) [\+ Compare](/compare?select=met-233i)[](https://app.peptrackerpro.com/?add=met-233i) ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/na-931) [\+ Compare](/compare?select=na-931)[](https://app.peptrackerpro.com/?add=na-931) ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/orforglipron) [\+ Compare](/compare?select=orforglipron)[](https://app.peptrackerpro.com/?add=orforglipron) ### Pemvidutide Medium Evidence A GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Liver Health](/benefits/liver-health)[Metabolism](/benefits/metabolism) [View Details](/peptides/pemvidutide) [\+ Compare](/compare?select=pemvidutide)[](https://app.peptrackerpro.com/?add=pemvidutide) ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[appetite-control](/benefits/appetite-control) [View Details](/peptides/petrelintide) [\+ Compare](/compare?select=petrelintide)[](https://app.peptrackerpro.com/?add=petrelintide) ### PF-08653944 Medium Evidence An ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/pf-08653944) [\+ Compare](/compare?select=pf-08653944)[](https://app.peptrackerpro.com/?add=pf-08653944) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Ribupatide Medium Evidence A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/ribupatide) [\+ Compare](/compare?select=ribupatide)[](https://app.peptrackerpro.com/?add=ribupatide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Taldefgrobep Alfa Low Evidence A novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026. [Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Muscle Growth](/benefits/muscle-growth)[body-composition](/benefits/body-composition)+1 more [View Details](/peptides/taldefgrobep) [\+ Compare](/compare?select=taldefgrobep)[](https://app.peptrackerpro.com/?add=taldefgrobep) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### Trevogrumab Medium Evidence Trevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass. [muscle-preservation](/benefits/muscle-preservation)[lean-mass-retention](/benefits/lean-mass-retention)[body-composition](/benefits/body-composition)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/trevogrumab) [\+ Compare](/compare?select=trevogrumab)[](https://app.peptrackerpro.com/?add=trevogrumab) ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ubt251) [\+ Compare](/compare?select=ubt251)[](https://app.peptrackerpro.com/?add=ubt251) ### VK2735 Medium Evidence An investigational oral and injectable GLP-1/GIP dual agonist showing 12.2% oral weight loss at 13 weeks at ECO 2026 and 14.7% injectable weight loss, with Phase 3 VANQUISH trials fully enrolled. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/vk2735) [\+ Compare](/compare?select=vk2735)[](https://app.peptrackerpro.com/?add=vk2735) ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/wve-007) [\+ Compare](/compare?select=wve-007)[](https://app.peptrackerpro.com/?add=wve-007) Track Your Research with PepTracker Pro [Try the Free App →](https://app.peptrackerpro.com) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.